Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 7/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968518 | 0.83 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL22420222 | 0.83 | PRKCA (0.43) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL21098352 | 0.77 | PRKCA (0.40) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL12199642 | 0.76 | MAPK1 (0.41) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL12780598 | 0.73 | CHRNB2 (0.42) | PRKCACHRNB2CHRNA4 | |
| SCHEMBL19435389 | 0.71 | CTSK (0.39) | PRKCAPRKCEPRKCQPRKCDCHRNB2 | |
| SCHEMBL9671738 | 0.69 | PRKCA (0.50) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL18650144 | 0.68 | CYP1A2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL25967321 | 0.67 | LMNA (0.42) | — | |
| SCHEMBL9575888 | 0.67 | EPHX1 (0.53) | PRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774099-B2 | Phospholipidation of imidazoquinolines and oxoadenines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774099-B2 | Phospholipidation of imidazoquinolines and oxoadenines | TLR7, TLR8, TLR9 | PRKCA 1732/4885PRKCE 2031/4885PRKCQ 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.